BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lenti MV, Cococcia S, Ghorayeb J, Di Sabatino A, Selinger CP. Stigmatisation and resilience in inflammatory bowel disease. Intern Emerg Med 2020;15:211-23. [PMID: 31893346 DOI: 10.1007/s11739-019-02268-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Philippou A, Birhanu B, Biello A, Keefer L, Gorbenko K. A Mixed-methods Assessment of the Impact of Insurance Issues on the Emotional and Physical Health of Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac022. [PMID: 35191977 DOI: 10.1093/ibd/izac022] [Reference Citation Analysis]
2 Muse K, Johnson E, David AL. A Feeling of Otherness: A Qualitative Research Synthesis Exploring the Lived Experiences of Stigma in Individuals with Inflammatory Bowel Disease. Int J Environ Res Public Health 2021;18:8038. [PMID: 34360327 DOI: 10.3390/ijerph18158038] [Reference Citation Analysis]
3 Keefer L, Gorbenko K, Siganporia T, Manning L, Tse S, Biello A, Ungaro R, Cohen LJ, Cohen BL, Dubinsky MC. Resilience-based Integrated IBD Care Is Associated With Reductions in Health Care Use and Opioids. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01225-8. [PMID: 34798332 DOI: 10.1016/j.cgh.2021.11.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Keefer L, Bedell A, Norton C, Hart AL. How Should Pain, Fatigue, and Emotional Wellness Be Incorporated Into Treatment Goals for Optimal Management of Inflammatory Bowel Disease? Gastroenterology 2022:S0016-5085(21)04073-7. [PMID: 34995528 DOI: 10.1053/j.gastro.2021.08.060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
5 Taft TH, Craven MR, Adler EP, Simons M, Nguyen L. Stigma experiences of patients living with gastroparesis. Neurogastroenterol Motil 2021;:e14223. [PMID: 34337831 DOI: 10.1111/nmo.14223] [Reference Citation Analysis]
6 Glynn H, Knowles SR. A Phenomenological Investigation of Trauma in 18 Adults Living With Inflammatory Bowel Disease. Clin Nurs Res. [DOI: 10.1177/10547738221075649] [Reference Citation Analysis]
7 Cococcia S, Lenti MV, Mengoli C, Klersy C, Borrelli de Andreis F, Secco M, Ghorayeb J, Delliponti M, Corazza GR, Di Sabatino A. Validation of the Italian translation of the perceived stigma scale and resilience assessment in inflammatory bowel disease patients. World J Gastroenterol 2021; 27(39): 6647-6658 [PMID: 34754158 DOI: 10.3748/wjg.v27.i39.6647] [Reference Citation Analysis]
8 Luo D, Zhou M, Sun L, Lin Z, Bian Q, Liu M, Ren S. Resilience as a Mediator of the Association Between Perceived Stigma and Quality of Life Among People With Inflammatory Bowel Disease. Front Psychiatry 2021;12:709295. [PMID: 34421685 DOI: 10.3389/fpsyt.2021.709295] [Reference Citation Analysis]
9 Tempchin J, Storch B, Reigada LC. Systematic review: Psychosocial factors of resilience in young people with inflammatory bowel disease. J Psychosom Res 2021;148:110558. [PMID: 34280678 DOI: 10.1016/j.jpsychores.2021.110558] [Reference Citation Analysis]
10 Lenti MV, Brera AS, Ballesio A, Croce G, Padovini L, Bertolino G, Di Sabatino A, Klersy C, Corazza GR. Resilience is associated with frailty and older age in hospitalised patients. BMC Geriatr 2022;22:569. [PMID: 35818046 DOI: 10.1186/s12877-022-03251-9] [Reference Citation Analysis]
11 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Lenti MV, Dolby V, Clark T, Hall V, Tattersall S, Fairhurst F, Kenneth C, Walker R, Kemp K, Borg-Bartolo S, Limdi JK, Taylor J, Townsend T, Subramanian S, Storey D, Assadsangabi A, Stansfield C, Smith P, Byrne D, De Silvestri A, Selinger CP. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment Pharmacol Ther 2021. [PMID: 34935160 DOI: 10.1111/apt.16742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]